These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 11823760

  • 21. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A, Basçi NE, Işimer A, Sayal A, Kayaalp SO.
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895
    [Abstract] [Full Text] [Related]

  • 22. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 23. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles.
    Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK.
    Pharmacogenetics; 1998 Dec; 8(6):529-41. PubMed ID: 9918137
    [Abstract] [Full Text] [Related]

  • 24. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.
    Panserat S, Sica L, Gérard N, Mathieu H, Jacqz-Aigrain E, Krishnamoorthy R.
    Br J Clin Pharmacol; 1999 Jan; 47(1):121-4. PubMed ID: 10073750
    [Abstract] [Full Text] [Related]

  • 25. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L.
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [Abstract] [Full Text] [Related]

  • 26. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D, Bréant D, Harlow J, Chowdry J, Lo-Guidice JM, Chevalier D, Cauffiez C, Lhermitte M, Blaney FE, Tucker GT, Broly F, Ellis SW.
    Proteins; 2005 May 01; 59(2):339-46. PubMed ID: 15726636
    [Abstract] [Full Text] [Related]

  • 27. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California.
    Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N, Lin KM.
    Pharmacogenetics; 2001 Aug 01; 11(6):489-99. PubMed ID: 11505219
    [Abstract] [Full Text] [Related]

  • 28. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.
    Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M.
    Pharmacogenetics; 2002 Jul 01; 12(5):375-83. PubMed ID: 12142727
    [Abstract] [Full Text] [Related]

  • 29. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.
    Bradford LD, Gaedigk A, Leeder JS.
    Psychopharmacol Bull; 1998 Jul 01; 34(4):797-804. PubMed ID: 10513455
    [Abstract] [Full Text] [Related]

  • 30. Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population.
    Cai WM, Chen B, Zhang WX.
    Clin Pharmacol Ther; 2007 Jan 01; 81(1):95-8. PubMed ID: 17186005
    [Abstract] [Full Text] [Related]

  • 31. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
    Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T.
    Pharmacogenetics; 2002 Aug 01; 12(6):465-72. PubMed ID: 12172215
    [Abstract] [Full Text] [Related]

  • 32. CYP2D6 polymorphism in a Mexican American population.
    Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM.
    Clin Pharmacol Ther; 2001 Dec 01; 70(6):552-60. PubMed ID: 11753272
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.
    Varela N, Quiñones LA, Stojanova J, Garay J, Cáceres D, Cespedes S, Sasso J, Miranda C.
    Pharmacol Res; 2015 Nov 01; 101():124-9. PubMed ID: 26211952
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.
    Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A.
    Eur J Clin Pharmacol; 2012 May 01; 68(5):637-44. PubMed ID: 22083166
    [Abstract] [Full Text] [Related]

  • 38. Induction of CYP2D6 in pregnancy.
    Wadelius M, Darj E, Frenne G, Rane A.
    Clin Pharmacol Ther; 1997 Oct 01; 62(4):400-7. PubMed ID: 9357391
    [Abstract] [Full Text] [Related]

  • 39. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R.
    Clin Pharmacokinet; 2011 May 01; 50(5):319-29. PubMed ID: 21456632
    [Abstract] [Full Text] [Related]

  • 40. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County.
    London SJ, Daly AK, Leathart JB, Navidi WC, Carpenter CC, Idle JR.
    Carcinogenesis; 1997 Jun 01; 18(6):1203-14. PubMed ID: 9214604
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.